Skuldtech, combining personalized medicine with high profitability:
Net Profit / Revenue ratio of 30% is forecasting for 2017.
Today, Skuldtech is searching new funds and new investors to:
A – Finance its R&D programs associated to personalized medicine, which will generate
79 million Euros of revenues in 2017,
B – Hire staff and invest to meet the increasing demand for its services in
genomics and pharmacogenomics.
To obtain more information about Skuldtech, please download it's "Executive Summary" (French/English).
If you require any additional information concerning our funding program,
please contact our financial department: +33(0)467 419 748.
Skuldtech is specialized in the discovery of
Biomarkers and the development of Diagnostics
focused on personalized medicine applications.
This expertise enables the company to provide
genomic, pharmacogenomic and transcriptomic services,
as well as innovative diagnostics
associated with new
therapeutics especially in
cancer, rare diseases and
infectious diseases.